
    
      Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on
      Day 1, Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented
      PD.The primary hypothesis of this study is that participants will have a longer Progression
      Free Survival (PFS), as assessed by Response Evaluation Criteria in Solid Tumors version 1.1
      (RECIST 1.1) when treated with Anlotinib plus Sintilimab(IBI 308).
    
  